Pharmacy availability increases emergency hormonal contraception use

2002 ◽  
Vol 391 (1) ◽  
pp. 12-12
Keyword(s):  
Hormonal Contraception ◽  
Contraception Use

Genital abnormalities, hormonal contraception, and HIV transmission risk in Rwandan serodifferent couples

2021 ◽  
Author(s):  
Kristin M Wall ◽  
Etienne Karita ◽  
Julien Nyombayire ◽  
Rosine Ingabire ◽  
Jeannine Mukamuyango ◽  
...  
Keyword(s):  
Hiv Transmission ◽  
Hormonal Contraception ◽  
Male Partner ◽  
Female Partner ◽  
Transmission Risk ◽  
Hiv Positive ◽  
Genital Ulceration ◽  
Factors Associated ◽  
Contraception Use ◽  
Hiv Acquisition

Abstract Background We explored the role of genital abnormalities and hormonal contraception in HIV transmission among heterosexual serodifferent couples in Rwanda. Methods From 2002-2011, non-antiretroviral treatment using HIV serodifferent couples were followed and sociodemographic and clinical data were collected, family planning provided, and HIV-negative partners retested. Couples were assessed for genital ulcers; non-ulcerative genital sexually transmitted infection (STI) including gonorrhea, chlamydia, and trichomoniasis; and non-STI vaginal infections including bacterial vaginosis and candida. Multivariable models evaluated associations between covariates and HIV transmission genetically linked to the index partner. Results Among 877 couples where the man was HIV-positive, 37 linked transmissions occurred. Factors associated with women’s HIV acquisition included female partner genital ulceration (adjusted hazard ratio [aHR]=14.1) and male partner non-ulcerative STI (aHR=8.6). Among 955 couples where the woman was HIV-positive, 46 linked transmissions occurred. Factors associated with men’s HIV acquisition included female partner non-ulcerative STI (aHR=4.4), non-STI vaginal dysbiosis (aHR=7.1), and male partner genital ulceration (aHR=2.6). Hormonal contraception use was not associated with HIV transmission or acquisition. Conclusions Our findings underscore the need for integrating HIV services with care for genital abnormalities. Barriers (e.g., cost for training, demand creation, advocacy, client education; provider time; clinic space) to joint HIV/STI testing need to be considered and addressed.

Association Between Maternal Hormonal Contraception Use and Central Nervous System Tumors in Children

JAMA ◽  
2022 ◽  
Vol 327 (1) ◽  
pp. 59
Author(s):  
Marie Hargreave ◽  
Lina S. Mørch ◽  
Jeanette F. Winther ◽  
Kjeld Schmiegelow ◽  
Susanne K. Kjaer
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Hormonal Contraception ◽  
Central Nervous System Tumors ◽  
Nervous System Tumors ◽  
Contraception Use

Contraception

2014 ◽  
pp. 1013-1018
Author(s):  
Jane S. Sillman ◽  
Ajay K. Singh
Keyword(s):  
United States ◽  
Emergency Contraception ◽  
Hormonal Contraception ◽  
Medical Knowledge ◽  
The United States ◽  
General Internist ◽  
Intrauterine Devices ◽  
Self Assessment ◽  
Barrier Methods ◽  
Contraception Use

The general internist needs to be up to date in contraception management. Each year nearly half of all pregnancies in the United States are unintended. Counseling about contraceptive options, provision of a back-up method, and information about emergency contraception can decrease the risk of unintended pregnancy. This chapter focuses on the aspects of contraception emphasized in Medical Knowledge Self-Assessment Program (MKSAP) 14: hormonal contraception, use of barrier methods, intrauterine devices, and emergency contraception.

scholarly journals Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077

2020 ◽  
Vol 85 (1) ◽  
pp. 93-97
Author(s):  
Cheríe S. Blair ◽  
Sue Li ◽  
Gordon Chau ◽  
Leslie Cottle ◽  
Paul Richardson ◽  
...  
Keyword(s):  
Hormonal Contraception ◽  
Contraception Use

scholarly journals Hormonal contraception and HIV acquisition among women: an updated systematic review

2020 ◽  
Vol 46 (1) ◽  
pp. 8-16 ◽  
Author(s):  
Kathryn M Curtis ◽  
Philip C Hannaford ◽  
Maria Isabel Rodriguez ◽  
Tsungai Chipato ◽  
Petrus S Steyn ◽  
...  
Keyword(s):  
Systematic Review ◽  
Observational Study ◽  
Oral Contraceptives ◽  
Hiv Risk ◽  
Contraceptive Method ◽  
Hormonal Contraception ◽  
Hormonal Contraceptive ◽  
Contraception Use ◽  
Hiv Acquisition ◽  
Risk Of Hiv Acquisition

ObjectiveTo update a 2016 systematic review on hormonal contraception use and HIV acquisition.MethodsWe searched Pubmed and Embase between 15 January 2016 and 26 June 2019 for longitudinal studies comparing incident HIV infection among women using a hormonal contraceptive method and either non-users or users of another specific hormonal contraceptive method. We extracted information from newly identified studies, assessed study quality, and updated forest plots and meta-analyses.ResultsIn addition to 31 previously included studies, five more were identified; three provided higher quality evidence. A randomised clinical trial (RCT) found no statistically significant differences in HIV risk among users of intramuscular depot medroxyprogesterone acetate (DMPA-IM), levonorgestrel implant (LNG implant) or the copper intrauterine device (Cu-IUD). An observational study found no statistically significant differences in HIV risk among women using DMPA, norethisterone enanthate (NET-EN), implants (type not specified) or Cu-IUD. Updated results from a previously included observational study continued to find a statistically significant increased HIV risk with oral contraceptives and DMPA compared with no contraceptive use, and found no association between LNG implant and HIV risk.ConclusionsHigh-quality RCT data comparing use of DMPA, LNG implant and Cu-IUD does not support previous concerns from observational studies that DMPA-IM use increases the risk of HIV acquisition. Use of other hormonal contraceptive methods (oral contraceptives, NET-EN and implants) is not associated with an increased risk of HIV acquisition.

scholarly journals Vestibular Anatomic Localization of Pain Sensitivity in Women with Insertional Dyspareunia: A Different Approach to Address the Variability of Painful Intercourse

2020 ◽  
Vol 9 (7) ◽  
pp. 2023
Author(s):  
Ahinoam Lev-Sagie ◽  
Osnat Wertman ◽  
Yoav Lavee ◽  
Michal Granot
Keyword(s):  
Pelvic Floor ◽  
Hormonal Contraception ◽  
Pelvic Floor Muscles ◽  
Pain Experience ◽  
Pain Hypersensitivity ◽  
Contraception Use ◽  
Painful Intercourse ◽  
Tip Test ◽  
Anatomic Localization

The pathophysiology underlying painful intercourse is challenging due to variability in manifestations of vulvar pain hypersensitivity. This study aimed to address whether the anatomic location of vestibular-provoked pain is associated with specific, possible causes for insertional dyspareunia. Women (n = 113) were assessed for “anterior” and “posterior” provoked vestibular pain based on vestibular tenderness location evoked by a Q-tip test. Pain evoked during vaginal intercourse, pain evoked by deep muscle palpation, and the severity of pelvic floor muscles hypertonicity were assessed. The role of potential confounders (vestibular atrophy, umbilical pain hypersensitivity, hyper-tonus of pelvic floor muscles and presence of a constricting hymenal-ring) was analyzed to define whether distinctive subgroups exist. Q-tip stimulation provoked posterior vestibular tenderness in all participants (6.20 ± 1.9). However, 41 patients also demonstrated anterior vestibular pain hypersensitivity (5.24 ± 1.5). This group (circumferential vestibular tenderness), presented with either vestibular atrophy associated with hormonal contraception use (n = 21), or augmented tactile umbilical-hypersensitivity (n = 20). The posterior-only vestibular tenderness group included either women with a constricting hymenal-ring (n = 37) or with pelvic floor hypertonicity (n = 35). Interestingly, pain evoked during intercourse did not differ between groups. Linear regression analyses revealed augmented coital pain experience, umbilical-hypersensitivity and vestibular atrophy predicted enhanced pain hypersensitivity evoked at the anterior, but not at the posterior vestibule (R = 0.497, p < 0.001). Distinguishing tactile hypersensitivity in anterior and posterior vestibule and recognition of additional nociceptive markers can lead to clinical subgrouping.

scholarly journals Hormonal contraception increases risk of breast tumor based on clinical breast examination among adult women

2017 ◽  
Vol 36 (2) ◽  
pp. 138
Author(s):  
Sulistyowati Tuminah Darjoko ◽  
Aprildah Nur Sapardin
Keyword(s):  
Breast Cancer ◽  
Total Cholesterol ◽  
Breast Tumor ◽  
Hormonal Contraception ◽  
Clinical Breast Examination ◽  
Adult Women ◽  
Breast Examination ◽  
Contraception Use ◽  
Clinical Breast ◽  
Advanced Analysis

<p>Background<br />In Indonesia, cancer prevalence according to the Basic Health Research 2013 was 1.4 per 1000 inhabitants and the most common cancer in hospitalized patients in 2010 was breast cancer (28.7%). Hormonal contraception (HC) use increases the breast cancer risk, even though HC has been used by 210 million women in the world. We aimed to define the association of HC with breast tumors based on clinical breast examination (CBE).</p><p>Methods<br />A case-control design using secondary data from the baseline of the Cohort Study on the Risk Factors of Non-Communicable Disease (RFNCD) in 2011-2012 in 5 villages in Central Bogor District, Bogor City. Samples consisted of 152 cases and 152 controls. Cases comprised palpable tumors in one or both breasts CBE (+). Controls had no tumors in both breasts /CBE(-). Data were analyzed by logistic regression.</p><p>Results<br />Odds Ratio (OR) of CBE + was 1.83 (95% CI: 1.11-3.04; p=0.019) for HC user and 1.62 (95% CI: 1.01-2.60; p=0.044) for blood total cholesterol level &lt;200 mg/dL. OR of group CBE(+) was 1.01 (current smoking) and 0.49 (former smoking) compared with nonsmoking (p=0.082); OR was also 1.21 for subjects with one child and 1.77 for those without children, compared with those who had ³2 children (p=0.454).</p><p>Conclusion <br />Hormonal contraception use increases breast tumor risk 1.8-fold after controlling for total cholesterol, smoking status and parity. With the several limitations of this advanced analysis, investigations focused on types and duration of HC use are still necessary.</p>

scholarly journals Epidemiological, Clinical, and Histopathological Features of Breast Cancer in Haiti

2018 ◽  
pp. 1-9 ◽  
Author(s):  
Vincent DeGennaro ◽  
Faiz Jiwani ◽  
Elizabeth Patberg ◽  
Martin Gibbs ◽  
Rachel Libby ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Black Women ◽  
Mortality Rate ◽  
Triple Negative ◽  
Hormonal Contraception ◽  
Stage Iv ◽  
The United States ◽  
Western Hemisphere ◽  
Her2 Positive ◽  
Contraception Use

Purpose Little is known about the epidemiology of breast cancer in developing countries, and Haiti has perhaps the least data of any country in the Western Hemisphere. Methods We conducted a retrospective review of all patients enrolled in an ongoing breast cancer treatment program in Port-au-Prince, Haiti, from July 1, 2013, through June 30, 2017. Data were drawn from each patient's electronic medical record, paper chart, and biopsy results. Results The records of 525 women with breast cancer were reviewed for this study. The median age at presentation was 49 years (n = 507). The risk factors observed were as follows: postmenopausal, 50.8% (n = 354); nulliparity, 15.7% (n = 338); hormonal contraception use, 35.0% (n = 309); never breastfed, 20.6% (n = 316); family history of any cancer, 22.0% (n = 295); overweight, 51.5% (n = 332); and smoking, 5.0% (n = 338). Of all those staged, 83.9% (n = 447) of the patients presented with stage III/IV disease and more than half delayed care for > 12 months after first noticing a breast mass. For the subset of tumors for which estrogen receptor (ER; n = 245) and human epidermal growth factor receptor 2 (HER2; n = 179) status was available, the prevalence of ER-positive tumors was 51.8%, of HER2-positive tumors was 19.6%, and of triple-negative tumors was 38.5%. The 12-month mortality rate (n = 425) was 18.4% overall and 27.5% for those who presented with stage IV disease. Median survival was not reached. Conclusion Breast cancer in Haiti presents at an early age and advanced stage. Triple-negative, ER-negative, and high-grade tumors are common. Delays in seeking care and incomplete treatment likely contribute to the high mortality rate; however, as in black women in the United States, the distribution of tumor types may contribute to disparate outcomes.

Sign in / Sign up

Export Citation Format

Share Document